*Mononegavirales*: A Huge Diversity of Similar Viruses {#Sec1}
======================================================

The order *Mononegavirales*, or nonsegmented negative strand RNA viruses (NNSV), comprises the families of *Rhabdoviridae*, *Paramyxoviridae*, *Filoviridae*, and *Bornaviridae*. Members of the *Rhabdoviridae* family have the broadest host range among the *Mononegavirales* and infect plants, insects, fish, aquatic, aerial, and terrestrial animals, and humans (for reviews, see Fu [@CR30]; Pringle [@CR82]). Remarkably, the only globally important human pathogen among rhabdoviruses is the rabies virus (RABV) of the genus *Lyssavirus*, which causes rabies encephalitis, a long-known, most dangerous and feared zoonotic disease. In spite of the availability of potent vaccines for animals and humans and effective postexposure treatments, rabies still causes more than 50,000 human deaths per year in rural areas of Asia and Africa, where it is mostly transmitted by rabid dogs. RABV is a typical member of the *Mononegavirales* in terms of virus organization and gene expression, and in this respect is closely related to the insect-transmitted vesicular stomatitis virus (VSV), a well-studied prototype rhabdovirus of the *Vesiculovirus* genus. However, the biology of RABV is unique in terms of direct transmission between mammals, a strict neurotropism, and an extremely broad host species range. These features are key to rabies biology, transmission, and pathogenesis, and represent severe obstacles in terms of RABV eradication.

In contrast to the *Rhabdoviridae*, numerous members of the *Paramyxoviridae* family have evolved to become human pathogens, such as the measles, mumps, parainfluenza, respiratory syncytial, Hendra, and Nipah viruses. An extremely valuable model paramyxovirus has always been Sendai virus (murine parainfluenza virus type 1; hemagglutinating virus of Japan, HVJ), the study of which has uncovered numerous traits of paramyxovirus biology (Nagai et al. [@CR72]), and the use of which as a biomedical tool is highly promising (see other chapters in this volume). Filoviruses such as Ebola and Marburg virus and Bornaviruses are animal viruses, which have not (yet) managed to become established in the human population (Lamb [@CR56]).

As different as individual members, genera, or families of *Mononegavirales* may be in terms of shape, biology, and pathogenesis, they all are but variations of a common theme of viral genome and particle organization and mode of gene expression. The single 10- to 20-kb RNA genomes and antigenomes of *Mononegavirales* exist in the form of a permanent helical ribonucleoprotein (RNP), in which the RNA is enclosed in a nucleoprotein (N, or NP). The information encoded is expressed by sequential and polar transcription of discrete subgenomic mRNAs from the RNPs (Fig. [1.1](#Fig1){ref-type="fig"}) (for detailed review, see Whelan et al. [@CR111]). The polymerase seems to be an RNP-dependent RNP polymerase for replication of RNPs and an RNP-dependent RNA polymerase for transcription of subgenomic mRNAs. It is composed of a large (L) multifunctional catalytic protein and a noncatalytic cofactor, mostly named phosphoprotein (P). The existence of such P protein distinguishes *Mononegavirales* from related segmented NSV such as bunyaviruses and arenaviruses. The most highly conserved N and L proteins of the *Mononegavirales* families still share common sequence blocks, whereas P proteins are much more variable. In addition to N, P, and L, *Mononegavirales* encode at least one matrix protein (M) and at least one transmembrane glycoprotein (e.g., G, GP, F), which make up the viral envelope, and which are predominantly engaged in formation of RNP-containing virions and infection of new target cells, respectively. Notably, the order of these five minimal genes (3′-N-P-M-G-L-5′) is strictly conserved in all *Mononegavirales* genomes (Fig. [1.1](#Fig1){ref-type="fig"}). This conservation is thought to reflect the stoichiometric need of the individual proteins, which is brought about through sequential and polar transcription. The modular organization of *Mononegavirales* genomes facilitates the acquisition of additional genes, mostly to internal positions, to specifically adapt to novel hosts and environments. In addition, individual genes of *Mononegavirales* may encode multiple gene products, as illustrated by the accessory proteins expressed from the paramyxovirus "P" gene (Sakaguchi et al. [@CR93]). The versatility of the common NNSV blueprint is illustrated by the fact that *Mononegavirales* have conquered different kingdoms of life, including plants and animals, as well as numerous niches within a single species. Fig. 1.1Recovery of *Mononegavirales* from plasmids. The standard protocol for recovery of *Mononegavirales* from cDNA involves simultaneous transfection of at least four plasmids into a cell, one comprising the full-length cDNA of the virus and three expression plasmids encoding helper virus proteins N, P, and L. The viral cDNA is oriented to give rise to a positive strand (antigenomic) RNA and is flanked by autocatalytic ribozyme sequences to produce the correct viral 5′- and 3′-ends upon transcription of the RNA by T7 RNA polymerase (encoded in transgenic cells, or from transfected plasmids) or by an endogenous cellular polymerase such as polymerase II. The virus-like RNA must be encapsulated into N protein to mimic a ribonucleoprotein (RNP) and to be recognized by the viral polymerase, which can act as a replicase (L--P--N complex) producing complementary RNPs, or as a transcriptase (L--P complex), producing nonencapsidated subgenomic mRNAs. Because the viral N, P, M, G, and L mRNAs are produced from the genome RNP, an autonomous infection cycle is initiated. Viral replication gives rise to an excess of genome RNPs, which can be used for assembly of novel virions

Synthetic Biology or "Reverse Genetics" of Viruses {#Sec2}
==================================================

Viruses and phages can be regarded as highly mobile genetic elements that need only a cell to translate the encoded information into protein. In the past, they have played a major role both as research objects and as tools in the development of modern gene technology. They are also at the forefront of synthetic biology. In fact, introducing authentic or modified nucleic acids or cDNA of viruses into a cell in many cases leads to initiation of an infectious cycle and ultimately in the creation of viruses never existing previously in nature. This technique was initially found to work for DNA viruses such as SV40 (Goff and Berg [@CR37]), retroviruses (Rothenberg et al. [@CR91]), and RNA phages (Taniguchi et al. [@CR102]), and for RNA viruses such as poliovirus (Racaniello and Baltimore [@CR83]), now known as "positive" strand RNA viruses. Importantly, the RNA of the positive strand RNA viruses, or the RNA derived from the introduced cDNA, can be immediately used for translation of all virus proteins. The negative strand RNA virus particles, however, were found to comprise RNA complementary to mRNA, and a specific polymerase (which is not present in cells) to transcribe individual subgenomic mRNAs upon entry into cells (Baltimore et al. [@CR4]; Baltimore [@CR3]). Obviously, the cDNA or cDNA-derived RNAs of *Mononegavirales* are not infectious because they are not suitable for translation of the necessary viral proteins by the cellular machinery. It was therefore noted by Racaniello and Baltimore (Racaniello and Baltimore [@CR83]) that "It is uncertain whether the application of recombinant DNA techniques to negative-strand RNA viruses (5) \[referring to Baltimore [@CR3]\] or viruses with multiple genome RNA's will also yield infectious cDNA." The term "reversed genetics" for this approach was introduced by Charles Weissmann and colleagues, describing methods for generating point mutations at predetermined sites of RNA or DNA genomes, specifically with Qbeta phage RNA as a template (Weissmann et al. [@CR109]). Fortunately, in spite of inherent drawbacks, reversed genetics has become available for negative strand RNA viruses as well, including members of all *Mononegavirales* virus families, the *Rhabdoviridae*, *Paramyxoviridae*, *Filoviridae*, and *Bornaviridae.*

Recovery of *Mononegavirales* from cDNA {#Sec3}
=======================================

Rescue and Use of Model Minigenomes {#Sec4}
-----------------------------------

Successful rescue of viruses from recombinant RNA relies on the expression of viral proteins from the viral RNA. In NNSV, expression of the encoded proteins is achieved by sequential transcription of individual mRNAs from the negative strand RNP. The proposed stop--restart model suggests entry of the polymerase exclusively at the 3′-end of the genomic (negative strand) RNP and the sequential transcription of a short nonmodified leader RNA specified by the 3′-end of the genome and of 5′-capped and 3′-polyadenylated mRNAs. The ends of the subgenomic RNAs are specified by conserved transcription stop/polyadenylation and restart signals at the gene borders. New RNPs are only formed upon accumulation of sufficient N protein, which apparently switches the transcriptase form of the polymerase to a replicase form of the polymerase. In this "replication" mode of the polymerase, synthesis of RNA and encapsidation into N protein is mechanistically linked, and the transcription signals are ignored.

The expression of viral proteins such as the polymerase components L and P is straightforward by using so-called "helper" plasmids or virus vectors providing the proteins in *trans* (Fig. [1.1](#Fig1){ref-type="fig"}). In contrast, the encapsidation of viral RNA by N protein, that is, the reconstitution of a functional RNP from premade RNA and N protein, also called "illegitimate encapsidation," turned out to be more difficult. Such artificial RNP must be able to serve as a template for the polymerase. Early experimental work mostly involved short defective interfering (DI) RNAs, or minigenomes comprising only the noncoding terminal promoter regions of *Mononegavirales* genomes. Initial encouraging success was obtained with the segmented influenza virus by transfection of an *in vitro* packaged genome segment (Luytjes et al. [@CR60]), and for the *Mononegavirales* with Sendai virus (Park et al. [@CR76]) by transfection of an *in vitro*-transcribed minigenome RNA into Sendai helper virus-infected cells, which resulted in expression of the minigenome-encoded reporter gene.

A major breakthrough was then the establishment of helper virus-free systems, in which DI- or minigenome RNAs and virus proteins were simultaneously expressed within cells from transfected circular plasmids (Pattnaik et al. [@CR79]; Pattnaik and Wertz [@CR77], [@CR78]). The system employed vaccinia virus (vv)-encoded phage T7 RNA polymerase and plasmids equipped with T7 RNA polymerase promoter and terminator sequences (Fuerst et al. [@CR31]). The critical ends of the model genome RNAs were generated by self-cleaving ribozymes (Fig. [1.1](#Fig1){ref-type="fig"}), such as the antigenome ribozyme of hepatitis delta virus (HDVagrz) (Perrotta and Been [@CR80]; Sharmeen et al. [@CR101]). The vv/T7 protein and RNA expression system paved the way for similar progress with minus strand RNA minigenomes of all families of the *Mononegavirales.* This achievement provided immediate experimental access to the clarification of fundamental and longstanding questions in the *Mononegavirales* field, including the identity and function of *cis*-acting signal sequences such as terminal promoters and transcription signals, or other RNA-based regulatory mechanisms, just to mention the rule of six (Calain and Roux [@CR15]; Vulliemoz and Roux [@CR108]), as well as the contribution of individual proteins to gene expression and replication. Moreover, minigenome systems are valuable tools for high-throughput screening of antivirals and provide a safe possibility to study aspects of highly dangerous viruses (Biacchesi [@CR6]; Conzelmann [@CR19]; Marriott and Easton [@CR61]; Theriault et al. [@CR105]; Whelan et al. [@CR111]).

Rescue of Recombinant Viruses from cDNA {#Sec5}
---------------------------------------

Although minigenome recovery in the described system worked reliably for many virus species, the desired generation of recombinant nondeficient viruses using the same approaches seemed to be out of reach for some time. Finally, an approach in which positive sense antigenome RNA rather than genome sense RNA of RABV was employed for initial encapsidation resulted in the successful recovery of the first negative strand RNA virus entirely from cDNA in our laboratory (Schnell et al. [@CR94]). In fact, this seemingly counterintuitive "positive approach" circumvents lethal common problems associated with genome sense RNA expression and encapsidation and was immediately applicable for recovery of other *Mononegavirales* as well, including rinderpest virus, respiratory syncytial virus, parainfluenza virus type 3, Sendai virus, SV5 or parainfluenza virus type 5, measles virus, VSV (Baron and Barrett [@CR5]; Collins et al. [@CR17]; Durbin et al. [@CR23]; Garcin et al. [@CR32]; He et al. [@CR40]; Hoffman and Banerjee [@CR41]; Kato et al. [@CR48]; Lawson et al. [@CR57]; Radecke et al. [@CR84]; Whelan et al. [@CR110]), and even of segmented NSV such as Bunyamwera virus (Bridgen and Elliott [@CR10]). Although initial encapsidation of antigenome RNA requires that an extra step of replication is supported by the coexpressed N, P, and L helper proteins (see Fig. [1.1](#Fig1){ref-type="fig"}), it avoids deleterious hybridization of viral genome RNA and the complementary helper protein mRNAs expressed simultaneously in the same cell (Conzelmann [@CR18]; Roberts and Rose [@CR90]; Schnell et al. [@CR94]). The resulting dsRNA is assumed not only to interfere with RNA encapsidation and helper protein translation but also to trigger innate antiviral immunity (Randall and Goodbourn [@CR86]; Rieder and Conzelmann [@CR87]). Although most laboratories confirmed a failure of *Mononegavirales* genome sense RNA rescue, in two highly optimized systems viruses could be rescued from both genome and antigenome RNAs, namely Sendai virus (Kato et al. [@CR48]) and HPIV-3 (Durbin et al. [@CR23]). In the former work, the magnitude of the antisense problem was nicely illustrated, as rescue efficiency with Sendai virus negative strand RNA was at least 100 fold less effective than with positive strand RNA (Kato et al. [@CR48]).

Technical Improvement of Virus Rescue Systems {#Sec6}
---------------------------------------------

The principle of the "classical" vaccinia virus/T7 virus rescue system turned out to work for viruses of all *Mononegavirales* families, including nonmammalian species such as fish rhabdoviruses (Biacchesi [@CR6]). Variations mostly included the use of other sources of T7 RNA polymerase, such as the host range-restricted vaccinia virus MVA-T7, or other poxvirus species, alleviating the need for active removal of the T7-encoding helper viruses just by passaging the recoveries in nonpermissive cells (Conzelmann [@CR19]). In addition, helper virus-free systems have been developed, based on transient expression of T7 RNA polymerase from plasmids or in stable cell lines. Particularly, BSR T7/5 cells (Buchholz et al. [@CR14]) are being widely used, as this cell clone combines the advantage of high-level T7 RNA polymerase expression, and of having a defect in the IRF3 gene, such that the antiviral interferon response is not induced (Conzelmann [@CR19]). In the absence of vaccinia virus capping and polyadenylation enzymes, T7 RNA polymerase transcripts have 5′-triphosphate ends, which is advantageous for generating virus-like antigenomes, but detrimental for helper protein translation. Therefore, T7 protein expression constructs should include an upstream IRES element, or helper proteins should be expressed from polymerase II promoter-driven plasmids.

Of particular importance for rescue of *Mononegavirales* are the ends of the RNA to be packaged, as already noticed in many minigenome systems. Particularly, a precise 3′-end was found critical for initial recognition by the viral polymerase and replication, whereas some extra nonviral nucleotides at the 5′-end were well tolerated (Pattnaik et al. [@CR79]). Therefore, in most *Mononegavirales* rescue systems T7 promoter transcripts have been employed that comprise three extra G residues to facilitate transcription initiation by T7 RNA polymerase (Conzelmann and Schnell [@CR20]; Pattnaik et al. [@CR79]). However, precise 5′-ends of the transcripts do more than compensate for lower transcript levels, as illustrated by highly efficient rescue of Sendai virus RNA lacking extra G residues (Kato et al. [@CR48]). More recently, hammerhead ribozymes (Blount and Uhlenbeck [@CR7]) are being increasingly employed for generation of exact 5′-ends of transcripts (Fig. [1.1](#Fig1){ref-type="fig"}). A direct comparison of RABV strain SAD L16 cDNA constructs yielding transcripts comprising three extra G residues or possessing correct 5′-ends generated by a hammerhead ribozyme revealed a tenfold advantage of the latter (Ghanem et al. [@CR35]). In this work it was also noticed that the cleavage efficiency of the HDV agrz used so far in almost all rescue systems is very low in transfected cells, and that only 10 % of the RNA has the right 3′-end available for initiation of replication. Exchange with a longer and more effective HDV ribozyme (SC) cleaving 90 % of intracellular transcripts again increased rescue efficiency more than tenfold. Moreover, the combination of hammerhead and SC HDVagrz in full-length clones of the RV SAD L16 (pSAD HH-L16-SC) had a synergistic effect and improved rescue by 100 fold, yielding the most efficient RABV rescue plasmid so far (Ghanem et al. [@CR35]).

The use of polymerases such as T7 RNA polymerase has the advantage of allowing transcription of transfected plasmids in the cytoplasm and therefore is ideal for the generation of viruses with a cytoplasmic replication cycle. Specifically, potential problems with nuclear export of RNA transcripts synthesized by cellular polymerases such as RNA Pol II are circumvented. Nevertheless, CMV promoter-driven rescue has been achieved for several cytoplasmic mammalian and fish rhabdoviruses (Ammayappan et al. [@CR1]; Biacchesi [@CR6]; Huang et al. [@CR44]; Inoue et al. [@CR45]; Ming et al. [@CR68]; Orbanz and Finke [@CR75]; Tao et al. [@CR103]), as well as paramyxoviruses (Martin et al. [@CR63]), suggesting the possibility to conditionally express viruses from host cell genome-encoded DNA in cultured cells or in animals.

Genetic Engineering of *Mononegavirales* Genomes {#Sec7}
================================================

Even the highly optimized *Mononegavirales* rescue systems remain less effective by orders of magnitude than positive strand RNA rescue. The major bottleneck is most probably a very poor rate of illegitimate RNA encapsidation by the N protein. Although this precludes a few applications, such as the use of *Mononegavirales* as cloning vectors for genetic libraries, it is sufficient for rescue of individual viruses, even severely attenuated viruses or gene-defective viruses, which require additional complementation in *trans*. Nonetheless, the possibilities of genetic manipulation of individual *Mononegavirales* as well as the applications are enormous as a result of their particular genome organization, lack of packaging size, the stability of their RNA genomes, and the lack of recombination with host sequences.

Mutation of Virus Functions: Host Immune Escape {#Sec8}
-----------------------------------------------

In the past two decades the possibility of site-directed mutagenesis of *Mononegavirales* has brought about hundreds of publications and a wealth of information on the structure, function, biology, virus--host interplay, and pathogenesis of individual *Mononegavirales.* One recent common topic is the interplay of viruses with the host innate immune system. This field has been fueled by tremendous progress in the identification of pattern recognition receptors (PRR) and details of the signaling pathways leading to the expression of type I and III interferons (IFN) and of proinflammatory cytokines.

IFN and proinflammatory cytokines are activated by two PRR families recognizing non-self viral RNA, the endosomal transmembrane Toll-like receptors (TLR 3, 7/8) and the cytoplasmic (RIG-I)-like helicases RIG-I (retinoic acid inducible gene-I, also known as DDX58) and MDA5 (melanoma differentiation-associated gene 5, also known as IFIH1 or helicard) (Kato et al. [@CR49]; Kawasaki et al. [@CR50]). The pathways for IFN induction merge in the activation of interferon regulatory factors (IRF) 3 and IRF7, which control transcription of type I and III IFN genes (Honda et al. [@CR42]; Onoguchi et al. [@CR74]; Yoneyama et al. [@CR114]). The pathways for induction of proinflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukins lead to canonical activation of NF-κB, which also supports transcription of the early IFNs (IFN-β, IFN-α4).

It turns out that *Mononegavirales* infection of cells is generally and effectively sensed by the ubiquitous RIG-I, which recognizes viral triphosphate RNAs (Cui et al. [@CR21]; Hornung et al. [@CR43]), that is, the leader RNA and possibly non-encapsidated genome RNAs of *Mononegavirales* (Gerlier and Lyles [@CR34]). Specific dsRNA patterns recognized by MDA5 remain elusive, and the usually minor contribution of MDA5 may differ for both virus species and host cell types (Bruns and Horvath [@CR11]; Loo and Gale [@CR59]). RIG-I or MDA5 activation by viral RNAs leads to their association with the mitochondrial protein IPS-1 (also known as MAVS, VISA, or Cardif), via CARD domains, and to the recruitment of a signaling complex in which IRF3 is phosphorylated by the kinases TBK-1 and IKKi (also known as IKKε) (Fitzgerald et al. [@CR28]; Sharma et al. [@CR100]). Ser386-phosphorylated IRF3 dimerizes and is imported into the nucleus where it drives transcription of IFN-β mRNA in conjunction with NF-κB and AP1 transcription factors (Ford and Thanos [@CR29]). The secreted IFN acts on cells by activating JAK/STAT signaling pathways (Platanias [@CR81]), which activate hundreds of IFN-stimulated genes (ISG), many of which have antiviral and immunomodulatory activities (Schoggins et al. [@CR98]; Theofilopoulos et al. [@CR104]).

Notably, even viruses with a very small coding capacity, such as the *Mononegavirales*, have evolved means to interfere with both IFN induction and IFN-mediated response and with ISG function, illustrating the power of the IFN system and the high evolutionary pressure for viruses to evolve suitable countermeasures (Gerlier and Lyles [@CR34]; Goodbourn and Randall [@CR39]; Randall and Goodbourn [@CR86]; Versteeg and Garcia-Sastre [@CR107]). Proper encapsidation of the viral RNA by N proteins into RNPs may be a common advantageous trait of *Mononegavirales* and largely prevent recognition by PRRs, but this requires a well-balanced synthesis of RNA and protein. If this delicate balance is disturbed, possibly in cell types not supporting RNA and protein synthesis equally well, or by overproduced DI RNAs, virus infection is easily recognized. In addition to shielding viral RNA, *Mononegavirales* have developed means to actively interfere with signal transduction. In mammalian *Mononegavirales*, these IFN antagonists are typically encoded by the P genes.

The RABV P protein, in addition to its functions as an N chaperone and polymerase cofactor, was found to have important roles in counteracting multiple specific steps of IFN gene expression, IFN-induced STAT signaling, and the function of antiviral proteins (Rieder and Conzelmann [@CR87]). Specifically, RABV P targets the activation of the transcription factors IRF3 and IRF7 and prevents their phosphorylation by the kinases TBK-1 and IKKi. The IRFs are therefore not able to dimerize, and their import into the nucleus and transcription of the IFN genes is precluded (Brzózka et al. [@CR12]). In addition, STAT-mediated transcription of ISGs is precluded in the presence of RABV P. After binding of IFN to the IFN receptor, STAT1 and STAT2 are phosphorylated at specific tyrosine residues by receptor-associated Janus kinases, which is a prerequisite for hetero-dimerization, association with IRF9, and nuclear import of the STATs (Platanias [@CR81]). Most remarkably, RABV P binds exclusively to tyrosine-phosphorylated STAT1 and STAT2, whereas in nonactivated cells an association of P with any STAT is not apparent (Brzózka et al. [@CR150]). Targeting of an already activated form of STAT is unprecedented and may appear critical in terms of timing. However, such conditional emergency activity may allow P to perform its many other functions in virus replication. The high relevance in the virus context of both IFN antagonistic functions was recently illustrated by generating recombinant viruses expressing low levels of P (Brzózka et al. [@CR12]), P mutants lacking specifically the IRF inhibitory function (Rieder et al. [@CR89]), or viruses defective in STAT inhibition (Ito et al. [@CR46]).

The P genes of paramyxoviruses such as Sendai virus encode, in addition to P, "accessory" proteins such as V or C, which largely take over IFN escape functions (Nagai et al. [@CR72]; Sakaguchi et al. [@CR93]) (see 10.1007/978-4-431-54556-9_2 for details). The V proteins of paramyxoviruses are translated from an edited P mRNA and possess a specific short C-terminal domain (V-CTD) of conserved structure and which is involved in binding and inhibiting a variety of target proteins involved in IFN induction (MDA5, IKKα, and IRF7), IFN signaling (STAT1, STAT2, Janus kinases), and NF-κB pathways (p65/RelA) (Gerlier and Lyles [@CR34]; Goodbourn and Randall [@CR39]; Motz et al. [@CR70]; Schuhmann et al. [@CR99]). The C proteins, which are expressed from an alternative reading frame of the P gene, seem to be involved in actively counteracting IFN (Sparrer et al. [@CR123]), but the C proteins of some viruses such as the measles virus may also be active in controlling viral RNA synthesis and preventing dsRNA accumulation, thereby limiting IFN responses (Boonyaratanakornkit et al. [@CR8]; Pfaller et al. [@CR122]). Notably, V and C proteins from different paramyxovirus species and genera may differ in their affinity to individual targets, probably reflecting adaptation to counteract pathways important in specific hosts, organs, and cell types (Versteeg and Garcia-Sastre [@CR107]).

In striking contrast to RABV and paramyxoviruses, innate immune escape of the insect-transmitted rhabdovirus VSV seems not to be determined by P gene functions. In VSV, rather, the M protein seems to represent the major factor, by shutting down host gene transcription and mRNA export (Rajani et al. [@CR85] and references therein).

The study of the structure of immune-stimulating RNAs of *Mononegavirales* and of the viral inhibitory mechanisms is not only shedding light on the nature of the innate immune system but offers directions toward the development of better attenuated and more immunogenic live vaccines. The elimination or modification of viral IFN antagonists by reverse genetics is yielding viruses that activate both innate and adaptive immune responses better than the wild-type (wt) virus.

Reorganization of Genomes: Vaccines, Vectors, Tracers, and Other Tools {#Sec9}
----------------------------------------------------------------------

The modular organization of genes in the *Mononegavirales* genomes (Fig. [1.1](#Fig1){ref-type="fig"}) allows easy deletion or insertion of extra genes without disturbing the expression machinery or virus formation. Gene cassettes comprising the transcriptional signals for transcription start and stop can be inserted between any of the viral genes, and in some viruses even in the 3′- and 5′-terminal positions. The major effect of extra transcription units in most viruses seems to be restricted to a modest transcriptional attenuation of the downstream genes. Thus, for example, up to four extra genes have been introduced successfully into the genomes of Sendai virus to simultaneously express multiple transcription factors for cell reprogramming (Nishimura et al. [@CR73]). Transcriptional attenuation can be compensated by equipping the downstream genes with gene borders known to cause less attenuation than others (Finke et al. [@CR26]). Alternative approaches include construction of single multi-cistronic transcription units encoding multiple proteins, by using picornaviral IRES elements or 2A-like sequences (Marschalek et al. [@CR62]). By manipulation of the genome and antigenome promoters, even rabies and Sendai viruses with an ambisense gene expression strategy have been recovered. These viruses express the set of viral proteins from the viral genome RNA and extra proteins from the viral antigenome RNA (Finke and Conzelmann [@CR25]; Le Mercier et al. [@CR58]).

As the position in the viral genome determines the relative expression levels, shifting of genes to different positions is a versatile and commonly used tool to study dose effects of both viral and foreign genes. In combination with other approaches such as gene deletion, the gene shift approach has been used in the case of RABV to identify so far unappreciated roles of M and P proteins as a regulator of viral transcription (Finke et al. [@CR27]) or as an interferon antagonist (Brzózka et al. [@CR12]), respectively.

### Vectors for Vaccines and Therapeutic Genes {#Sec10}

The ability to express foreign or heterologous genes and antigens is the basis for the development of heterologous or multivalent vaccines. Particularly, many *Mononegavirales* are well known to induce strong humoral, cellular, and mucosal immune responses. Established human vaccine virus strains, such as the measles Schwarz strain of the Edmonston lineage, or animal viruses that do not cause disease in humans such as Sendai virus or Newcastle disease virus, seem to be immediately suited as promising carriers. In fact, numerous viral antigens from the major agents threatening human health, including human immunodeficiency virus (HIV)-1, Ebola virus, influenza virus, and SARS virus, hepatitis C virus (HCV), and HBV, have been expressed from these viruses (Brandler et al. [@CR9]; Geisbert and Feldmann [@CR33]; Khattar et al. [@CR51]; Yu et al. [@CR115]), and the first human trials are awaited. Also, recombinant RABV is being exploited as a vector vaccine, particularly for immunization against HIV-1 (Gomme et al. [@CR38]), because completely attenuated RABV variants are now available. The RABV G protein is the major virulence factor of RABV and is responsible for the pronounced neurotropism and neuroinvasiveness of the virus. Mutations affecting the arginine 333 residue of the G protein dramatically alter the cell tropism and render RABV avirulent, even after intracerebral injection (Mebatsion [@CR64]). Similarly, RABV lacking the IRF3 inhibitory function are completely attenuated after infection in mouse brains (Rieder et al. [@CR89]).

### Envelope Switching {#Sec11}

A particular advantage of *Mononegavirales* is their amenability to envelope switching. As confirmed early by gene deletion mutants, the G proteins of the rhabdoviruses RABV and VSV are not essential for virus formation and budding of virions, although they may contribute to the efficiency of the process (Mebatsion et al. [@CR66]; Schnell et al. [@CR97]). Moreover, they can be entirely replaced by foreign type I transmembrane proteins. By using viral proteins active in receptor binding and membrane fusion, virions with a novel tropism or host range can be generated (Johnson et al. [@CR47]; Mebatsion and Conzelmann [@CR65]; Schnell et al. [@CR95]). Even viruses specifically targeting cells infected with another virus can be generated (Mebatsion et al. [@CR67]; Schnell et al. [@CR96]). Natural paramyxoviruses have been long known for phenotypic mixing, or formation of pseudo-type viruses in coinfections (Kimura [@CR52]), and are similarly amenable to artificial envelope swapping (for a recent paper, see Mourez et al. [@CR71]). However, the requirements for incorporation of heterologous envelope proteins may differ for viruses. In contrast to VSV, which readily incorporates numerous type I transmembrane proteins (Schnell et al. [@CR97]), efficient incorporation into RABV requires a C-tail sequence and structure similar to that of RABV G (Mebatsion and Conzelmann [@CR65]).

Envelope swapping is a strategy extremely useful for various approaches. For vaccination purposes, sequential application of viruses possessing different envelopes avoids immune recognition and allows repeated use of the same vector backbone. In addition, the glycoproteins of highly dangerous viruses can be studied safely by using pseudo-type virions. Appropriate de- and retargeting of viruses is especially important in the field of oncolytic virotherapy. Envelope switching can involve the generation of chimeric "surrogate" viruses, in which a novel G-protein gene replaces the autologous gene, or of pseudo-type viruses, where the G gene is deleted and the protein is provided in *trans*. The latter is a safe approach, as single-round vectors are being generated that can infect a single cell but cannot spread further.

### Oncolytic Virotherapy {#Sec12}

A highly promising field for some recombinant *Mononegavirales* is oncolytic virotherapy, which means the use of viruses to selectively infect and damage cancerous tissues without causing harm to normal tissues (Russell et al. [@CR92]). Preferred replication in transformed cells is partly caused by their genetic defects in innate immune responses, such as impaired STAT signaling or induction of apoptosis, that is, in major antiviral mechanisms. Viruses with defects in their IFN antagonists (such as paramyxovirus V proteins, or VSV M protein) therefore may replicate effectively in such cancer cells, whereas they are attenuated in normal tissue in which the antiviral mechanisms are intact. Some viruses, such as Newcastle disease virus and mumps virus, seem to have a strong natural preference for cancer cells, but other viruses such as measles, VSV, or Sendai virus can be readily engineered to make them more cancer specific (Cattaneo et al. [@CR16]; Kinoh et al. [@CR53]). Engineering of oncolytic viruses may include retargeting by destroying the natural receptor-binding domains of the viral envelope proteins in combination with displaying polypeptide ligands on the surface to facilitate infection of tumor cells overexpressing the targeted receptor. An outstanding series of retargeted measles viruses has been created accordingly, targeting various antigens overexpressed on tumor cells (Cattaneo et al. [@CR16]). An alternative approach is complete envelope switching, that is, the complete exchange of the viral surface proteins. Promising examples of envelope switching include the use of oncolytic VSV carrying the envelope of LCMV, enhancing the infectivity for glioma cells and minimizing neurotropism (Muik et al. [@CR121]). In the case of Sendai virus, tumor specificity could be enhanced by exploiting the need for proteolytic activation of the fusion protein (F). Specifically, the F-cleavage site was modified in such a way that it was cleaved by a protease highly expressed only in tumor cells (Morodomi et al. [@CR69]).

### Monosynaptic Tracing of Neurons with RABV: Envelope Swapping in Situ {#Sec13}

The large group of *Mononegavirales* comprises viruses with highly diverse biological traits and thus represents an almost unlimited source of tools for all kinds of basic research and biomedical applications. In the past two decades of *Mononegavirales* reverse genetics, Sendai virus has emerged as a prime example for the broad and huge potential of this virus, as impressively illustrated in detail in the following chapters. Major inherent advantages of Sendai virus include its apathogenicity for humans and broad host and tissue range. Also, however, virulent viruses and, more explicitly, specific pathogenic traits of these viruses can be exploited for research. One example is the unparalleled neurotropism of RABV, which makes this virus a fierce pathogen but also offers unique possibilities for the study of the nervous system. RABV is entirely adapted to the nervous system of its hosts and---importantly---is completely dependent on the integrity of the peripheral nervous system to reach the brain where it replicates best and where it can elicit behavioral changes of the host to facilitate virus transmission within the population. Upon peripheral infection, RABV is taken up by the axon ends of neurons via endocytosis and is retrogradely transported in axonal transport vesicles toward the cell body (Klingen et al. [@CR54]). Upon membrane fusion and release of the RNP into the cytoplasm, replication takes place without severe effects on the viability and function of neurons (Lafon [@CR55]). Remarkably, newly assembled virions seem to be released exclusively at functional synapses where they can enter second-order neurons at the presynaptic membrane (Astic et al. [@CR2]; Ugolini [@CR106]). For trans-synaptic transmission, the RABV G protein is required (Etessami et al. [@CR24]).

This exclusive trans-synaptic spread is unique among viruses and therefore natural RABV has been used for years as a "polysynaptic" tracer in specialized laboratories (Dum and Strick [@CR22]). Direct synaptic connections of individual neurons, however, cannot be easily determined with conventional nonviral or viral tracers. The availability of RABV reverse genetics and progress in vector construction and virus retargeting, however, has more recently allowed the development of the first system for "monosynaptic" tracing of direct neuronal connections (Wickersham et al. [@CR113]) (Fig. [1.2](#Fig2){ref-type="fig"}). Fig. 1.2Monosynaptic tracing of neuronal circuits with rabies virus (RABV) ΔG. The exclusive trans-synaptic transmission of RABV is being exploited for mapping of direct connections between neurons. A starter neuron (*yellow*) that provides RABV G protein (*blue*) is transmitting a G gene-deleted RABV expressing eGFP (SAD ΔG-eGFP) via a synapse to presynaptic neurons (*green*). Because the G protein is not produced in the presynaptic neurons, the virus cannot be transmitted further. Selective infection of the postsynaptic starter neuron can be achieved, for example, by expression of a specific receptor (here, TVA), making cells permissive for infection with SAD ΔG-eGFP pseudo-typed with a retroviral envelope protein (EnvA)

The system involves targeted infection of a defined (postsynaptic) neuron with a G gene-deficient recombinant RABV (ΔG RABV) expressing a fluorescent protein such as green fluorescent protein (GFP). Specific targeting of the postsynaptic neuron is achieved, for example, by expression of the avian TVA receptor, and infection with ΔG RABV pseudo-typed with EnvA of an avian retrovirus that uses the TVA receptor for entry (Fig. [1.2](#Fig2){ref-type="fig"}). Additional expression of RABV G protein supports trans-synaptic transfer of the virus to synaptically connected (presynaptic) neurons. As no G is expressed in the presynaptic cells, the virus does not spread further. This safe ΔG RABV system is now being used widely by neurobiologists not only to dissect sensory and motor circuits in the nervous system of various animal models but also to read out and modulate the activity of single neurons and of neuronal circuits (Ginger et al. [@CR36]; Wickersham and Feinberg [@CR112]). It is expected that recombinant RABV in this way greatly contributes to the understanding of how our most complex brains work.

Conclusions {#Sec14}
===========

After an intricate birth phase, reverse genetics of *Mononegavirales* has become a standard technique to study this group of medically important viruses. Tremendous progress has been made subsequently in understanding the biology of these viruses, the interplay with their hosts, and the mechanisms of pathogenicity. It is becoming increasingly clear that the host innate immune system and specific viral counteractions profoundly shape virus--host relationships. Reverse genetics can now be used to make friends from foes, by converting the viruses to safe vaccines and biomedical tools. The group of *Mononegavirales* represents an exceptional source of diverse viruses for diverse applications, for example, rabies virus neurotracing. Sendai virus, in particular, has emerged in the past years as a cornucopia for many novel and innovative biomedical tools, as impressively illustrated in the following chapters of this volume.
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